药物过度使用性头痛研究进展

doi:10.3969/j.issn.1672-6731.2022.02.009

摘要/Abstract

摘要： 药物过度使用性头痛是涉及医学、经济学和社会学的全球性公共卫生问题。高频或慢性原发性头痛是药物过度使用性头痛的危险因素，加强对原发性头痛的治疗和管理、提高对药物过度使用性头痛的认识、避免过度使用镇痛药，是预防药物过度使用性头痛的方法。本文综述药物过度使用性头痛的诊断、临床特点、药物过度使用和药物依赖、治疗等，以为临床治疗提供新的思路。

关键词: 头痛, 药物过量, 物质相关性障碍, 综述

Abstract: Medication-overuse headache (MOH) is a global public health problem involving medicine, economics and sociology. High frequency or chronic primary headache is a risk factor of MOH. The methods to prevent MOH are to strengthen the treatment and management of primary headache, to improve the understanding of MOH, and to avoid overuse of analgesics. This article reviews the diagnosis, clinical features, drug overuse and drug dependence, and treatment of MOH.

Key words: Headache, Drug overdose, Substance-related disorders, Review

陈春富. 药物过度使用性头痛研究进展[J]. 中国现代神经疾病杂志, 2022, 22(2): 110-115.

CHEN Chun-fu. Research progress of medication-overuse headache[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2022, 22(2): 110-115.

http://journal11.magtechjournal.com/cjcnn/CN/Y2022/V22/I2/110

参考文献

[1] Westergaard ML, Munksgaard SB, Bendtsen L, Jensen RH. Medication-overuse headache:a perspective review[J]. Ther Adv Drug Saf, 2016, 7:147-158.
[2] Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barré J, Katsarava Z, Lainez JM, Lampl C, Lantéri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Andrée C. The cost of headache disorders in Europe:the Eurolight project[J]. Eur J Neurol, 2012, 19:703-711.
[3] Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain[J]. Cephalalgia, 1988, 8 Suppl 7:1-96.
[4] Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders:2nd edition[J]. Cephalalgia, 2004, 24 Suppl 1:9-160.
[5] Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition[J]. Cephalalgia, 2018, 38:1-211.
[6] Moavero R, Stornelli M, Papetti L, Ursitti F, Ferilli MAN, Balestri M, Sforza G, Tarantino S, Vigevano F, Valeriani M. Medication overuse withdrawal in children and adolescents does not always improve headache:a cross-sectional study[J]. Front Neurol, 2020, 11:823.
[7] Shnayder NA, Sharavii VB, Petrova MM, Moskaleva PV, Pozhilenkova EA, Kaskaeva DS, Tutynina OV, Popova TE, Garganeeva NP, Nasyrova RF. Candidate genes and proteomic biomarkers of serum and urine in medication-overuse headache[J]. Int J Mol Sci, 2021, 22:9024.
[8] Russell MB. Epidemiology and management of medication-overuse headache in the general population[J]. Neurol Sci, 2019, 40(Suppl 1):23-26.
[9] Diener HC, Holle D, Solbach K, Gaul C. Medication-overuse headache:risk factors, pathophysiology and management[J]. Nat Rev Neurol, 2016, 12:575-583.
[10] Green MW. Medication overuse headache[J]. Curr Opin Neurol, 2021, 34:378-383.
[11] Salhofer-Polanyi S, Zebenholzer K, Berndl T, Kastrati K, Raab S, Schweitzer P, Stria T, Topic P, Wöber C. Medication overuse headache in 787 patients admitted for inpatient treatment over a period of 32 years[J]. Cephalalgia, 2020, 40:808-817.
[12] Schwedt TJ, Buse DC, Argoff CE, Reed ML, Fanning KM, Hussar CR, Adams AM, Lipton RB. Medication overuse and headache burden:results from the CaMEO study[J]. Neurol Clin Pract, 2021, 11:216-226.
[13] Diener HC, Antonaci F, Braschinsky M, Evers S, Jensen R, Lainez M, Kristoffersen ES, Tassorelli C, Ryliskiene K, Petersen JA. European Academy of Neurology guideline on the management of medication-overuse headache[J]. Eur J Neurol, 2020, 27:1102-1116.
[14] Wang YF, Yu CC, Kuan AS, Chen SP, Wang SJ. Association between suicidal risks and medication-overuse headache in chronic migraine:a cross-sectional study[J]. J Headache Pain, 2021, 22:36.
[15] Find NL, Terlizzi R, Munksgaard SB, Bendtsen L, Tassorelli C, Nappi G, Katsarava Z, Lainez M, Goicochea MT, Shand B, Fadic R, Spadafora S, Pagani M, Jensen R; COMOESTAS Consortium. Medication overuse headache in Europe and Latin America:general demographic and clinical characteristics, referral pathways and national distribution of painkillers in a descriptive, multinational, multicenter study[J]. J Headache Pain, 2015, 17:20.
[16] Ashina M. Migraine[J]. N Engl J Med, 2020, 383:1866-1876.
[17] Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine:a longitudinal population-based study[J]. Headache, 2008, 48:1157-1168.
[18] Saengjaroentham C, Strother LC, Dripps I, Sultan Jabir MR, Pradhan A, Goadsby PJ, Holland PR. Differential medication overuse risk of novel anti-migraine therapeutics[J]. Brain, 2020, 143:2681-2688.
[19] Migliore S, Paolucci M, Quintiliani L, Altamura C, Maffi S, D'Aurizio G, Curcio G, Vernieri F. Psychopathological comorbidities and clinical variables in patients with medication overuse headache[J]. Front Hum Neurosci, 2020, 14:571035.
[20] American Psychiatric Association. Diagnostic and statistical manual of mental disorders[M]. 5th ed. Washington DC:American Psychiatric Publishing, 2013:481-490.
[21] Kristoffersen ES, Benth JŠ, Straand J, Russell MB, Lundqvist C. Validity of self-reported assessment of severity of dependence scale in medication:overuse headache[J]. Scand J Pain, 2019, 19:837-841.
[22] Corand V, Moisset X, Radat F, Lucas C; working group. Medication overuse headache:updating of the French recommendations regarding the treatment strategies[J]. Rev Neurol (Paris), 2021, 177:760-764.
[23] Evers S, Jensen R; European Federation of Neurological Societies. Treatment of medication overuse headache:guideline of the EFNS headache panel[J]. Eur J Neurol, 2011, 18:1115-1121.
[24] Diener HC, Dodick D, Evers S, Holle D, Jensen RH, Lipton RB, Porreca F, Silberstein S, Schwedt T. Pathophysiology, prevention, and treatment of medication overuse headache[J]. Lancet Neurol, 2019, 18:891-902.
[25] Carlsen LN, Munksgaard SB, Nielsen M, Engelstoft IMS, Westergaard ML, Bendtsen L, Jensen RH. Comparison of 3 treatment strategies for medication overuse headache:a randomized clinical trial[J]. JAMA Neurol, 2020, 77:1069-1078.
[26] Rouw C, Munksgaard SB, Engelstoft IMS, Nielsen M, Westergaard ML, Jensen RH, Bendtsen L, Carlsen LN. Dependence-like behaviour in patients treated for medication overuse headache:a prospective open-label randomized controlled trial[J]. Eur J Pain, 2021, 25:852-861.
[27] Steiner TJ, Jensen R, Katsarava Z, Linde M, MacGregor EA, Osipova V, Paemeleire K, Olesen J, Peters M, Martelletti P. Aids to management of headache disorders in primary care (2nd edition):on behalf of the European Headache Federation and Lifting The Burden:the Global Campaign against Headache[J]. J Headache Pain, 2019, 20:57.
[28] Tepper SJ, Diener HC, Ashina M, Brandes JL, Friedman DI, Reuter U, Cheng S, Nilsen J, Leonardi DK, Lenz RA, Mikol DD. Erenumab in chronic migraine with medication overuse:subgroup analysis of a randomized trial[J]. Neurology, 2019, 92:e2309-2320.
[29] Caronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M, Pozo-Rosich P. Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse:real-life effectiveness and predictors of response at 6 months[J]. J Headache Pain, 2021, 22:120.
[30] Tepper SJ, Ashina M, Reuter U, Hallström Y, Broessner G, Bonner JH, Picard H, Cheng S, Chou DE, Zhang F, Klatt J, Mikol DD. Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab:post-hoc analyses of episodic and chronic migraine clinical trials[J]. J Headache Pain, 2021, 22:81.
[31] Pensato U, Baraldi C, Favoni V, Cainazzo MM, Torelli P, Querzani P, Pascazio A, Mascarella D, Matteo E, Quintana S, Asioli GM, Cortelli P, Pierangeli G, Guerzoni S, Cevoli S. Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache[J]. Neurol Sci, 2022, 43:1273-1280.
[32] Cainazzo MM, Baraldi C, Ferrari A, Lo Castro F, Pani L, Guerzoni S. Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache:an observational, retrospective, 12-month real-life study[J]. Neurol Sci, 2021, 42:4193-4202.
[33] Curone M, Tullo V, Bussone G. Effectiveness of erenumab in chronic migraine patients with associated medication overuse headache:a prospective observational study[J]. Neurol Sci, 2020, 41(Suppl 2):509-510.
[34] Schiano di Cola F, Rao R, Caratozzolo S, Di Cesare M, Venturelli E, Balducci U, Sidoti V, Pari E, Costanzi C, di Summa A, Sixt GJ, D'Adda E, Liberini P, Padovani A. Erenumab efficacy in chronic migraine and medication overuse:a real-life multicentric Italian observational study[J]. Neurol Sci, 2020, 41(Suppl 2):489-490.
[35] Talbot J, Stuckey R, Crawford L, Weatherby S, Mullin S. Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment-real world outcomes[J]. J Headache Pain, 2021, 22:5.
[36] Dodick DW, Doty EG, Aurora SK, Ruff DD, Stauffer VL, Jedynak J, Dong Y, Pearlman EM. Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine[J]. Cephalalgia, 2021, 41:340-352.
[37] Kristoffersen ES, Straand J, Russell MB, Lundqvist C. Disability, anxiety and depression in patients with medication-overuse headache in primary care:the BIMOH study[J]. Eur J Neurol, 2016, 23 Suppl 1:28-35.
[38] Bottiroli S, Viana M, Sances G, Ghiotto N, Guaschino E, Galli F, Vegni E, Pazzi S, Nappi G, Tassorelli C. Psychological factors associated with failure of detoxification treatment in chronic headache associated with medication overuse[J]. Cephalalgia, 2016, 36:1356-1365.
[39] Bottiroli S, Allena M, Sances G, De Icco R, Avenali M, Fadic R, Katsarava Z, Lainez MJ, Goicochea MT, Jensen RH, Nappi G, Tassorelli C; Comoestas Consortium. Changes in anxiety and depression symptoms associated to the outcome of MOH:a post-hoc analysis of the Comoestas Project[J]. Cephalalgia, 2018, 38:646-654.
[40] Pijpers JA, Kies DA, van Zwet EW, Rosendaal FR, Terwindt GM. Behavioural intervention in medication overuse headache:a concealed double-blind randomised controlled trial[J]. Eur J Neurol, 2022[.Epub ahead of print]

选择文件类型/文献管理软件名称

选择包含的内容

2 药物过度使用性头痛研究进展

Research progress of medication-overuse headache

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	薛蓉, 张轩. 睡眠障碍对脑血管病的影响[J]. 中国现代神经疾病杂志, 2023, 23(8): 659-662.
[2]	张鹏, 陈涛, 许莉. 成人失眠认知行为疗法关键技术与流程改进建议[J]. 中国现代神经疾病杂志, 2023, 23(8): 663-667.
[3]	张轩, 薛蓉. 特发性快速眼动睡眠期行为障碍向神经系统变性疾病转化的生物学标志物研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 668-673.
[4]	刘引, 汤永红, 翟锦霞, 邱媛. 慢性低度炎症与睡眠障碍研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 674-677.
[5]	于洁洋, 张亚男, 李惠敏, 黄真灿, 李宛儒, 王赞. 发作性睡病与焦虑研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 678-682.
[6]	库成心, 邓丽影, 谢亮. 缺血性卒中继发日间过度思睡研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 683-686.
[7]	姜佳凤, 赵莲花, 赵伟. 褪黑素在阿尔茨海默病病理损害机制中的作用[J]. 中国现代神经疾病杂志, 2023, 23(8): 687-692.
[8]	黄沛, 王刚. 功能性帕金森综合征诊断与治疗[J]. 中国现代神经疾病杂志, 2023, 23(8): 738-741.
[9]	洪涛, 唐斌. 如何成为一名优秀的颅底外科医师[J]. 中国现代神经疾病杂志, 2023, 23(7): 571-574.
[10]	张庆硕, 宋丹丹, 周世越, 张金璐, 韩晓旭, 许顺良. 功能性步态障碍诊断与治疗[J]. 中国现代神经疾病杂志, 2023, 23(7): 604-609.
[11]	潘希娟, 邢英琦, 刘玉梅. 脑小血管病影像学评分方法[J]. 中国现代神经疾病杂志, 2023, 23(7): 633-637.
[12]	俞淑凤, 李宁, 徐健, 王鹏. 颈动脉漂浮血栓相关缺血性卒中诊断与治疗进展[J]. 中国现代神经疾病杂志, 2023, 23(7): 638-642.
[13]	魏俊吉. 神经外科重症医学规范化诊断与治疗[J]. 中国现代神经疾病杂志, 2023, 23(6): 477-478.
[14]	杜倩, 邓素君, 邹姗, 金珺, 周青山. 宏基因组第二代测序技术在重症中枢神经系统感染中的应用[J]. 中国现代神经疾病杂志, 2023, 23(6): 479-484.
[15]	曲鑫, 赵浩, 尚峰, 王宁. 神经重症目标温度管理[J]. 中国现代神经疾病杂志, 2023, 23(6): 485-489.

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

2 药物过度使用性头痛研究进展

Research progress of medication-overuse headache

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价